Knees next for Mesoblast
Tuesday, 12 August, 2008
Preclinical trials conducted by Mesoblast [ASX: MSB] have shown that the company's adult stem cells are capable of regenerating damaged knee cartilage in a post-menopausal osteoarthritis large animal model.
A single injection of adult stem cells was able to repair and regenerate knee cartilage in ewes with well established osteoarthritis even though the cells were administered three months after initial joint damage.
This effect has yet to be demonstrated by any competing products on the market, the company said.
Mesoblast executive director Professor Silviu Itescu said the results meant the company would now target both post-menopausal and post-traumatic knee osteoarthritis for product commercialisation.
Common medications linked to adverse breast cancer outcomes
An international study has found concerning evidence about the impact of a range of common...
Saliva-based biosensor could improve heart failure detection
Scientists have created a biosensor that can rapidly detect the heart failure biomarker S100A7 in...
Melanoma-causing mutation can lie dormant in healthy skin
Researchers found many examples of the mutation in normal skin, including skin next to a mole and...
